Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The combination melphalan-prednisone-thalidomide (MPT) is considered a standard therapy for patients with myeloma who are ineligible for stem-cell transplantation. However, emerging data on the use of lenalidomide and low-dose dexamethasone warrant a prospective comparison of the two approaches. METHODS: We randomly assigned 1623 patients to lenalidomide and dexamethasone in 28-day cycles until disease progression (535 patients), to the same combination for 72 weeks (18 cycles; 541 patients), or to MPT for 72 weeks (547 patients). The primary end point was progression-free survival with continuous lenalidomide-dexamethasone versus MPT. RESULTS: The median progression-free survival was 25.5 months with continuous lenalidomide-dexamethasone, 20.7 months with 18 cycles of lenalidomide-dexamethasone, and 21.2 months with MPT (hazard ratio for the risk of progression or death, 0.72 for continuous lenalidomide-dexamethasone vs. MPT and 0.70 for continuous lenalidomide-dexamethasone vs. 18 cycles of lenalidomide-dexamethasone; P<0.001 for both comparisons). Continuous lenalidomide-dexamethasone was superior to MPT for all secondary efficacy end points, including overall survival (at the interim analysis). Overall survival at 4 years was 59% with continuous lenalidomide-dexamethasone, 56% with 18 cycles of lenalidomide-dexamethasone, and 51% with MPT. Grade 3 or 4 adverse events were somewhat less frequent with continuous lenalidomide-dexamethasone than with MPT (70% vs. 78%). As compared with MPT, continuous lenalidomide-dexamethasone was associated with fewer hematologic and neurologic toxic events, a moderate increase in infections, and fewer second primary hematologic cancers. CONCLUSIONS: As compared with MPT, continuous lenalidomide-dexamethasone given until disease progression was associated with a significant improvement in progression-free survival, with an overall survival benefit at the interim analysis, among patients with newly diagnosed multiple myeloma who were ineligible for stem-cell transplantation. (Funded by Intergroupe, Francophone du Myélome and Celgene; FIRST ClinicalTrials.gov number, NCT00689936; European Union Drug Regulating Authorities Clinical Trials number, 2007-004823-39.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Lenalidomide plus dexamethasone is a standard treatment for patients with newly diagnosed multiple myeloma who are ineligible for autologous stem-cell transplantation.”
From Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma (2019) · cites this paper as [5]
In the citing paper
“However, the incidence of grade 3 or 4 infections was 29% with lenalidomide and dexamethasone in the primary analysis of the FIRST trial,5 which was consistent with the incidence in our trial (32.1% in the daratumumab group and 23.3% in the control group).”
From Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma (2019) · cites this paper as [5]
In the citing paper
“In this subset of patients, maintenance therapy with proteasome inhibitors alone or in combination with lenalidomide seems to be more effective than single-agent lenalidomide34,35.”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [34]
In the citing paper
“Patients with high-risk cytogenetic features might be the only exception, although they do derive a progression-free survival (PFS) benefit34,35.”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [34]
In the citing paper
“The most worrisome adverse effect observed in studies of lenalidomide maintenance therapy is an up to six-fold increase in the risk of second primary malignancies, in particular, MDS and acute myeloid leukaemia (AML): 5.3% versus 0.8% with placebo or observation34.”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [34]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., McFadden, E. T., & Carbone, P. P. (1982) · AMERICAN JOURNAL OF CLINICAL ONCOLOGY · doi:10.1097/00000421-198212000-00014 · Cited by 11,647
A Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
International uniform response criteria for multiple myeloma
Durie, B. G. M., Harousseau, J.-L., Miguel, J. S., Bladé, J., Barlogie, B., Anderson, K., Gertz, M., Dimopoulos, M., Westin, J., Sonneveld, P., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404284 · Cited by 2,632
Self-citationPalumbo, A., & Anderson, K. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1011442 · Cited by 2,326
Self-citationRaje, N., & Anderson, K. C. (2000) · Current Treatment Options in Oncology · doi:10.1007/s11864-000-0017-x · Cited by 2,163
Self-citationBortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma
San Miguel, J. F., Schlag, R., Khuageva, N. K., Dimopoulos, M. A., Shpilberg, O., Kropff, M., Spicka, I., Petrucci, M. T., Palumbo, A., Samoilova, O. S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801479 · Cited by 1,899
Self-citationGroup sequential methods in the design and analysis of clinical trials
POCOCK, S. J. (1977) · Biometrika · doi:10.1093/biomet/64.2.191 · Cited by 1,831
Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma
Dimopoulos, M., Spencer, A., Attal, M., Prince, H. M., Harousseau, J.-L., Dmoszynska, A., Miguel, J. S., Hellmann, A., Facon, T., Foà, R., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070594 · Cited by 1,450
Self-citationLenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America
Weber, D. M., Chen, C., Niesvizky, R., Wang, M., Belch, A., Stadtmauer, E. A., Siegel, D., Borrello, I., Rajkumar, S. V., Chanan-Khan, A. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070596 · Cited by 1,233
Self-citation
Cited by
Items 101–200 of 793
Rangan, P., Lobo, F., Parrella, E., Rochette, N. C., Morselli, M., Stephen, T., Cremonini, A. L., Tagliafico, L., Persia, A., Caffa, I., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111417 · Cited by 79
Hou, J., Jin, J., Xu, Y., Wu, D., Ke, X., Zhou, D., Lu, J., Du, X., Chen, X., Li, J., et al. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0501-4 · Cited by 71
“Outcomes are improving further through the treatment paradigm of long-term or continuous therapy [9, 10].”
BackgroundSelf-citationTreatment of patients with multiple myeloma progressing on frontline-therapy with lenalidomide
Moreau, P., Zamagni, E., & Mateos, M.-V. (2019) · Blood Cancer Journal · doi:10.1038/s41408-019-0200-1 · Cited by 68
Self-citationHow I treat first relapse of myeloma
Harousseau, J. L., & Attal, M. (2017) · Blood · doi:10.1182/blood-2017-03-726703 · Cited by 67
Self-citationOsteoclast Immunosuppressive Effects in Multiple Myeloma: Role of Programmed Cell Death Ligand 1
Tai, Y., Cho, S., & Anderson, K. C. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01822 · Cited by 70
“Proc Natl Acad Sci U S A (2008) 105(7):2658–63.”
Self-citationBooth, C. M., Eisenhauer, E. A., Gyawali, B., & Tannock, I. F. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.01423 · Cited by 78
A phase 2 study of rituximab plus lenalidomide for mucosa-associated lymphoid tissue lymphoma
Kiesewetter, B., Willenbacher, E., Willenbacher, W., Egle, A., Neumeister, P., Voskova, D., Mayerhoefer, M. E., Simonitsch‐Klupp, I., Melchardt, T., Greil, R., et al. (2016) · Blood · doi:10.1182/blood-2016-06-720599 · Cited by 67
Rosiñol, L., Oriol, A., Ríos, R., Blanchard, M. J., Jarque, I., Bargay, J., Hernández, M. T., Cabañas, V., Carrillo‐Cruz, E., Sureda, A. M., et al. (2023) · Blood · doi:10.1182/blood.2022019531 · Cited by 70
Self-citationMateos, M., Richardson, P. G. G., Dimopoulos, M. A., Palumbo, A. P., Anderson, K. C., Shi, H., Elliott, J., Dow, E., de Velde, H. J. V., Niculescu, L., et al. (2015) · American Journal of Hematology · doi:10.1002/ajh.23933 · Cited by 72
“Similar results have been seen with other MM therapies, such as the benefit of continuous lenalidomide-dexamethasone maintenance therapy until disease progression rather than for only 18 28-day cycles [13].”
ResultSelf-citationTeh, B. W., Harrison, S. J., Worth, L. J., Thursky, K., & Slavin, M. A. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.07.025 · Cited by 72
Facon, T. T. F., Moreau, P., Weisel, K. C., Goldschmidt, H., Usmani, S. Z., Chari, A., Plesner, T., Orlowski, R. Z., Bahlis, N. J., Basu, S., et al. (2025) · Leukemia · doi:10.1038/s41375-024-02505-2 · Cited by 86
Self-citationTreatment and disease‐related complications in multiple myeloma: Implications for survivorship
Chakraborty, R., & Majhail, N. S. (2020) · American Journal of Hematology · doi:10.1002/ajh.25764 · Cited by 73
“of infectionswith currently used anti-myeloma agents are summarized in Table 1.(10,11,16,34,48-54) A validated predictive model for early ≥grade 3 infections has been developed in the context of treatment with IMiDs.”
MethodIxazomib for the treatment of multiple myeloma
Richardson, P. G. G., Zweegman, S., O’Donnell, E., Laubach, J. P., Raje, N. S., Voorhees, P. M., Ferrari, R. H., Skácel, T., Kumar, S. K., & Lonial, S. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1528229 · Cited by 65
The Danish National Multiple Myeloma Registry
Gimsing, P., Holmström, M. O., Klausen, T., Andersen, N. F., Gregersen, H., Pedersen, R. S., Plesner, T., Pedersen, P. T., Frederiksen, M., Frølund, U. C., et al. (2016) · Clinical Epidemiology · doi:10.2147/clep.s99463 · Cited by 64
Observational study of multiple myeloma in Latin America
On behalf of the International Myeloma Working Group Latin America, Hungria, V., Maiolino, Â., Martınez, G., Duarte, G. O., Bittencourt, R., Peters, L. G. B., Colleoni, G. W. B., de Oliveira, L. C. O., Crusoé, E. D. Q., et al. (2016) · Annals of Hematology · doi:10.1007/s00277-016-2866-9 · Cited by 65
Pegourié, B., Karlin, L., Benboubker, L., Orsini‐Piocelle, F., Tiab, M., Auger‐Quittet, S., Rodon, P., Royer, B., Leleu, X. P., Bareau, B., et al. (2019) · American Journal of Hematology · doi:10.1002/ajh.25459 · Cited by 67
Self-citationWang, Q., Zhao, D., Xian, M., Wang, Z., Bi, E., Su, P., Qian, J., Ma, X., Yang, M., Liu, L., et al. (2020) · Blood · doi:10.1182/blood.2020005795 · Cited by 63
Kumar, S. K., Moreau, P., Hari, P., Mateos, M., Ludwig, H., Shustik, C., Masszi, T., Spencer, A. G., Hájek, R., Romeril, K. R., et al. (2017) · British Journal of Haematology · doi:10.1111/bjh.14733 · Cited by 59
Self-citationSive, J. I., Cuthill, K., Hunter, H. M., Kazmi, M. A., Pratt, G., Smith, D., & British Society of Haematology (2021) · British Journal of Haematology · doi:10.1111/bjh.17410 · Cited by 70
Current developments in immunotherapy in the treatment of multiple myeloma
Köhler, M., Greil, C., Hudecek, M., Lonial, S., Raje, N. S., Wäsch, R., & Engelhardt, M. M. (2018) · Cancer · doi:10.1002/cncr.31243 · Cited by 61
“These agents have already significantly improved response rates, progression-free survival (PFS), and overall survival (OS)(3) and are mostly well tolerated even by elderly patients.(13,14) However, MM still remains incurable, and this is independent of patients’ age and frailty; RRMM patients especially are still in…”
BackgroundUpdate on the role of lenalidomide in patients with multiple myeloma
Holstein, S. A., Suman, V. J., & McCarthy, P. L. (2018) · Therapeutic Advances in Hematology · doi:10.1177/2040620718775629 · Cited by 61
Melflufen: A Peptide–Drug Conjugate for the Treatment of Multiple Myeloma
Mateos, M.-V., Bladé, J., Bringhen, S., Ocio, E. M., Efebera, Y., Pour, L., Gay, F., Sonneveld, P., Gullbo, J., & Richardson, P. G. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9103120 · Cited by 57
Sequential vs alternating administration of VMP and Rd in elderly patients with newly diagnosed MM
Mateos, M., Martínez‐López, J., Hernández, M.-T., Ocio, E. M., Rosiñol, L., Martínez, R., Teruel, A. I., Gutierrez, N. C., Ramos, M.-L. M., Oriol, A., et al. (2015) · Blood · doi:10.1182/blood-2015-08-666537 · Cited by 68
Self-citationKumar, S. K., LaPlant, B. R., Reeder, C. B., Roy, V., Halvorson, A. E., Buadi, F. K., Gertz, M. A., Bergsagel, P. L., Dispenzieri, A. A., Thompson, M. A., et al. (2016) · Blood · doi:10.1182/blood-2016-05-717769 · Cited by 60
Self-citationHow I manage the toxicities of myeloma drugs
Delforge, M., & Ludwig, H. (2017) · Blood · doi:10.1182/blood-2017-01-725705 · Cited by 58
Self-citationEngelhardt, M. M., Ihorst, G., Landgren, O., Pantić, M., Reinhardt, H., Waldschmidt, J. M., May, A. M., Schumacher, M. C., Kleber, M., & Wäsch, R. (2015) · Haematologica · doi:10.3324/haematol.2015.127548 · Cited by 55
“In solid tumor patients, we confirmed main tumor clusters.(5,8,9,12,39) Most of our solid tumor patients had received combined modality treatment; therefore, therapy-related mechanisms may play a role in the development of myeloma.”
BackgroundResultWang, Y., Yang, F., Shen, Y., Zhang, W., Wang, J., Chang, V. T.-S., Andersson, B. S., Qazilbash, M. H., Champlin, R. E., Berenson, J. R., et al. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djv342 · Cited by 60
“In the more recent FIRST trial, continuous Len/Dex was superior to limited Len/Dex (18 cycles), leading to prolonged PFS but not OS (35).”
BackgroundEpidemiology, genetics and treatment of multiple myeloma and precursor diseases
Hemminki, K., Försti, A., Houlston, R. S., & Sud, A. (2021) · International Journal of Cancer · doi:10.1002/ijc.33762 · Cited by 70
“Current regimens used range from bortezomib-based triplet therapy possibly with dose attenuation,(194,195) lenalidomidebased triplet therapy,(196) and doublet therapy such lenalidomide and dexamethasone.(197)”
Evaluating Daratumumab in the Treatment of Multiple Myeloma: Safety, Efficacy and Place in Therapy
Dima, D., Dower, J., Comenzo, R. L., & Varga, C. (2020) · Cancer Management and Research · doi:10.2147/cmar.s212526 · Cited by 59
Imaging and bone marrow assessments improve minimal residual disease prediction in multiple myeloma
Alonso, R., Cedena, M., Gómez‐Grande, A., Ríos, R., Moraleda, J. M., Cabañas, V., Moreno, M. J., López‐Jiménez, J., Martín‐Moro, F., Sanz, A., et al. (2019) · American Journal of Hematology · doi:10.1002/ajh.25507 · Cited by 52
Characteristics of exceptional responders to lenalidomide-based therapy in multiple myeloma
Vu, T., Gonsalves, W., Kumar, S., Dispenzieri, A., Lacy, M. Q., Buadi, F., Gertz, M. A., & Rajkumar, S. V. (2015) · Blood Cancer Journal · doi:10.1038/bcj.2015.91 · Cited by 51
Self-citationMoreau, P., Kolb, B., Attal, M., Caillot, D., Benboubker, L., Tiab, M., Touzeau, C., Leleu, X., Roussel, M., Chaleteix, C., et al. (2015) · Blood · doi:10.1182/blood-2015-02-626168 · Cited by 51
Self-citationUpdate of thrombosis in multiple myeloma
Leebeek, F. W. G. (2016) · Thrombosis Research · doi:10.1016/s0049-3848(16)30103-7 · Cited by 53
Determining therapeutic susceptibility in multiple myeloma by single-cell mass accumulation
Çetin, A. E., Stevens, M. M., Calistri, N. L., Fulciniti, M., Olçum, S., Kimmerling, R. J., Munshi, N. C., & Manalis, S. R. (2017) · Nature Communications · doi:10.1038/s41467-017-01593-2 · Cited by 58
Pros and cons of frontline autologous transplant in multiple myeloma: the debate over timing
Kumar, S. K., Buadi, F. K., & Rajkumar, S. V. (2018) · Blood · doi:10.1182/blood-2018-08-825349 · Cited by 55
Multiple myeloma in the very elderly patient: challenges and solutions
King, A. J., Eyre, T. A., Sharpley, F. A., Watson, C. S., Ramasamy, K., & Willan, J. (2016) · Clinical Interventions in Aging · doi:10.2147/cia.s89465 · Cited by 58
Approach to the Older Adult With Multiple Myeloma
Mina, R., Bringhen, S., Wildes, T. M., Zweegman, S., & Rosko, A. E. (2019) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_239067 · Cited by 55
Recognition of early mortality in multiple myeloma by a prediction matrix
Terebelo, H. R., Srinivasan, S. S., Narang, M., Abonour, R., Gasparetto, C., TOOMEY, K. E., Hardin, J. W., Larkins, G., Kitali, A., Rifkin, R. M., et al. (2017) · American Journal of Hematology · doi:10.1002/ajh.24796 · Cited by 50
“Oncology Group (ECOG) PS was estimated using conversion criteria for Karnofsky PS scores recommended by the European Society for Medical Oncology.20,21 A second external validation was conducted using data from the phase 3 FIRST (Frontline Investigation of Lenalidomide1Dexamethasone Versus Standard Thalidomide) trial…”
MethodInfluentialMultiple Myeloma: From Front-Line to Relapsed Therapies
Moreau, P., & Touzeau, C. (2015) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2015.35.e504 · Cited by 48
Self-citationDimopoulos, M. A., Richardson, P. G., Bahlis, N. J., Grosicki, S., Cavo, M., Beksaç, M., Legieć, W., Liberati, A. M., Goldschmidt, H., Belch, A., et al. (2022) · The Lancet Haematology · doi:10.1016/s2352-3026(22)00103-x · Cited by 48
“7,8 9-12 Elotuzumab is a humanized immunoglobulin G1 immunostimulatory monoclonal antibody that targets signalling lymphocytic activation molecule family member 7, a glycoprotein highly expressed on myeloma cells, natural killer (NK) cells, and some immune cells, but not on other normal tissues.”
Self-citationA comparison of salvage infusional chemotherapy regimens for recurrent/refractory multiple myeloma
Griffin, P. T., Ho, V. Q., Fulp, W. J., Nishihori, T., Shain, K. H., Alsina, M., & Baz, R. (2015) · Cancer · doi:10.1002/cncr.29533 · Cited by 50
Chakraborty, R., Riaz, I. B., Malik, S. U., Marneni, N., Garcia, A. M., Anwer, F., Khorana, A. A., Rajkumar, S. V., Kumar, S. K., Murad, M. H., et al. (2020) · Cancer · doi:10.1002/cncr.32682 · Cited by 51
Activity of lenalidomide in mantle cell lymphoma can be explained by NK cell‐mediated cytotoxicity
Hagner, P. R., Chiu, H., Ortiz, M., Apollonio, B., Wang, M., Couto, S. S., Waldman, M. F., Flynt, E., Ramsay, A. G., Trotter, M. W. B., et al. (2017) · British Journal of Haematology · doi:10.1111/bjh.14866 · Cited by 53
Leleu, X. P., Masszi, T., Bahlis, N. J., Viterbo, L., Baker, B., Gimsing, P., Maisnar, V., Samoilova, O. S., Rosiñol, L., Langer, C., et al. (2018) · American Journal of Hematology · doi:10.1002/ajh.25134 · Cited by 50
Self-citationKrönke, J., Kuchenbauer, F., Kull, M., Teleanu, V, Bullinger, L., Bunjes, D., Greiner, A., Kolmus, S., Köpff, S., Schreder, M., et al. (2017) · Leukemia · doi:10.1038/leu.2016.384 · Cited by 46
“All the patients were scheduled to undergo autologous SCT following standard high-dose melphalan (200 mg/m2).”
InfluentialChakraborty, R., Cannella, L., Cottone, F., & Efficace, F. (2020) · The Lancet Haematology · doi:10.1016/s2352-3026(20)30292-1 · Cited by 54
Health-related quality of life in patients with multiple myeloma - does it matter?
Kvam, A. K., & Waage, A. (2015) · Haematologica · doi:10.3324/haematol.2015.127860 · Cited by 56
“The randomized phase III trial compared the efficacy and safety of lenalidomide in combination with low-dose dexamethasone (Rd), with melphalan, prednisone and thalidomide (MPT).(9) In this three-arm study, 1,623 patients were randomized to Rd until disease progression (535 patients), to the same combination for 72 we…”
MethodLenalidomide long-term neurotoxicity: Clinical and neurophysiologic prospective study
Torre, C. D., Zambello, R., Cacciavillani, M., Campagnolo, M., Berno, T., Salvalaggio, A., March, E. D., Barilà, G., Lico, A., Lucchetta, M., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000003093 · Cited by 47
“This is an important feature in light of the imminent introduction of lenalidomide as a first line of therapy in Europe as for the United States.(21,22) In addition, considering the clinical advantages of patients after first-line remission to be maintained in prolonged low-dose lenalidomide, the lack of relevant neur…”
BackgroundGay, F., Oliva, S., Petrucci, M. T., Montefusco, V., Conticello, C., Musto, P., Catalano, L., Evangelista, A., Spada, S., Campbell, P. J., et al. (2016) · Leukemia · doi:10.1038/leu.2016.381 · Cited by 49
Dimopoulos, M., Wang, M., Maisnar, V., Minarik, J., Bensinger, W., Mateos, M.-V., Obreja, M., Blaedel, J., & Moreau, P. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0583-7 · Cited by 44
Self-citationBringhen, S., D’Agostino, M., París, L., Ballanti, S., Pescosta, N., Spada, S., Pezzatti, S., Grasso, M., Rota‐Scalabrini, D., Rosa, L. D., et al. (2019) · Haematologica · doi:10.3324/haematol.2019.226407 · Cited by 44
“* At least one among deletion 17p [del(17p)], translocation (4;14) [t(4;14)] or translo-”
BackgroundDaratumumab in untreated newly diagnosed multiple myeloma
Abdallah, N. H., & Kumar, S. K. (2019) · Therapeutic Advances in Hematology · doi:10.1177/2040620719894871 · Cited by 51
Perrot, A., Facon, T. T. F., Plesner, T., Usmani, S. Z., Kumar, S. K., Bahlis, N. J., Hulin, C., Orlowski, R. Z., Nahi, H., Mollee, P. N., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.01370 · Cited by 50
Self-citationImmunotherapy in Multiple Myeloma
Soekojo, C. Y., Ooi, M. G. M., Mel, S. D., & Chng, W. J. (2020) · Cells · doi:10.3390/cells9030601 · Cited by 49
“The FIRST trial showed that lenalidomide-dexamethasone as a continuous treatment was superior to MPT (melphalan, prednisone, thalidomide) [24].”
MethodThromboprophylaxis in multiple myeloma patients treated with lenalidomide – A systematic review
Al‐Ani, F., Bastida, J. M., Mateos, M., & Louzada, M. (2016) · Thrombosis Research · doi:10.1016/j.thromres.2016.03.006 · Cited by 43
Patel, K. K., Giri, S., Parker, T. L., Bar, N., Neparidze, N., & Huntington, S. F. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.01849 · Cited by 46
Advantages and drawbacks of dexamethasone in glioblastoma multiforme
Afshari, A. R., Sanati, M., Aminyavari, S., Shakeri, F., Bibak, B., Keshavarzi, Z., Soukhtanloo, M., Jalili‐Nik, M., Sadeghi, M. M., Mollazadeh, H., et al. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103625 · Cited by 49
Ríos, R., Sáinz, J., Martínez‐López, J., Puerta, J. M., Chang, D. Y. L., Rodríguez, T., Garrido, P., Silva, J. L. G. D. V., Romero, A., Moratalla, L., et al. (2016) · American Journal of Hematology · doi:10.1002/ajh.24389 · Cited by 49
Hari, P., Romanus, D., Palumbo, A. P., Luptakova, K., Rifkin, R. M., Tran, L. M., Raju, A., Farrelly, E., Noga, S. J., Blazer, M. A., et al. (2018) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2017.12.012 · Cited by 42
“The phase III The Front-line Investigation of Revlimid and Dexamethasone versus Standard Thalidomide (FIRST) trial demonstrated that continuous frontline therapy with lenalidomide plus dexamethasone until disease progression leads to better progression-free survival (PFS) compared with fixed-duration therapy.(4) Also,…”
BackgroundPerspectives on the Risk-Stratified Treatment of Multiple Myeloma
Davies, F. E., Pawlyn, C., Usmani, S. Z., Miguel, J. F. S., Einsele, H., Boyle, E. M., Corre, J., Auclair, D., Cho, H. J., Lonial, S., et al. (2022) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-21-0205 · Cited by 48
“With current treatments it is now possible to achieve median PFS and OS for transplant-eligible (TE) patients of 4 to 6 and 6 to 9+ years, respectively [IFM2009 study (76) VRd+ASCT (PFS median 47 months, OS at 8 years 62%), GRIFFIN study (77) Dara-VRd+ASCT (PFS at 2 years 96%, OS at 2 years >96%) and Cassiopeia study…”
BackgroundSelf-citationSetia, N., Almuqdadi, H. T. A., & Abid, M. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.116041 · Cited by 45
Myeloma in Elderly Patients: When Less Is More and More Is More
Rosko, A. E., Giralt, S., Mateos, M., & Dispenzieri, A. A. (2017) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbk_175171 · Cited by 52
Self-citationDimopoulos, M. A., Cheung, M. C., Roussel, M., Liu, T., Gamberi, B., Kolb, B., Derigs, H. G., Eom, H., Belhadj, K., Lenain, P., et al. (2016) · Haematologica · doi:10.3324/haematol.2015.133629 · Cited by 40
“Renal failure 2 (2) 3 (3) 1 (1) 7 (3) 3 (1) 3 (1) 3 (2) 4 (3) 5 (4) 1 (2) 8 (17) 7 (13)”
Self-citationIntegration of Novel Agents into the Care of Patients with Multiple Myeloma
Orlowski, R. Z., & Lonial, S. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0861 · Cited by 44
“For transplantineligible patients after induction therapy, continued treatment with lenalidomide alone or with RD should be considered (66, 67), whereas bortezomib alone (68) or with other agents (69) are additional options, although they have not been validated in placebo-controlled trials.”
BackgroundLuo, J., Gagne, J. J., Landon, J. E., Avorn, J., & Kesselheim, A. S. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.10.018 · Cited by 38
The power of proteasome inhibition in multiple myeloma
Guerrero-Garcia, T. A., Gandolfi, S., Laubach, J. P., Hideshima, T., Chauhan, D., Mitsiades, C. S., Anderson, K. C., & Richardson, P. G. G. (2018) · Expert Review of Proteomics · doi:10.1080/14789450.2018.1543595 · Cited by 38
“line transplant-ineligible setting following the results of the FIRST phase 3 trial [72].”
ResultSelf-citationProlonged lenalidomide maintenance therapy improves the depth of response in multiple myeloma
Alonso, R., Cedena, M., Wong, S. W. K., Shah, N. D., Ríos, R., Moraleda, J. M., López‐Jiménez, J., García, C., Bahri, N., Valeri, A., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020001508 · Cited by 41
Harnessing the Immune System Against Multiple Myeloma: Challenges and Opportunities
Yamamoto, L., Amodio, N., Gullà, A., & Anderson, K. C. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.606368 · Cited by 42
“Recent approval of monoclonal antibodies (moAb) for the treatment of both newly diagnosed (NDMM) and relapsed/refractory (RRMM) MM patients highlights the fundamental role of therapies targeting the immunosuppressive microenvironment.”
InfluentialSelf-citationInflammation and infection in plasma cell disorders: how pathogens shape the fate of patients
Caro, J., Braunstein, M. J., Williams, L. S., Bruno, B., Kaminetzky, D., Siegel, A., Razzo, B. M., Alfandari, S., Morgan, G. J., Davies, F. E., et al. (2022) · Leukemia · doi:10.1038/s41375-021-01506-9 · Cited by 43
“Age ≥ 65 years FIRST Benboubker, 2014 [111] 1623 Continuous Rd vs.”
BackgroundArikian, S. R., Milentijevic, D., Binder, G., Gibson, C. J., Hu, X., Nagarwala, Y. M., Hussein, M. A., Corvino, F. A., Surinach, A., & Usmani, S. Z. (2015) · Current Medical Research and Opinion · doi:10.1185/03007995.2015.1031732 · Cited by 37
Larsen, R. F., Jarden, M., Minet, L. R., Frølund, U. C., & Abildgaard, N. (2019) · Pilot and Feasibility Studies · doi:10.1186/s40814-019-0518-2 · Cited by 40
Piechotta, V., Jakob, T., Langer, P. H., Monsef, I., Scheid, C., Estcourt, L. J., Ocheni, S., Theurich, S., Kuhr, K., Scheckel, B., et al. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013487 · Cited by 42
Hu, Y., Liu, H., Fang, C., Li, C., Xhyliu, F., Dysert, H., Bodo, J., Habermehl, G. K., Russell, B. E., Li, W., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-1077 · Cited by 44
Self-citationFu, W., Bang, S., Huang, H., Kım, K., Li, W., An, G., Lee, J., Cai, Z., Jin, J., Wang, Y., et al. (2023) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2023.02.009 · Cited by 36
Self-citationLaubach, J. P., Prada, C. P., Richardson, P. G. G., & Longo, D. (2016) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.550 · Cited by 41
Takamatsu, H. (2017) · Journal of Clinical Medicine · doi:10.3390/jcm6100091 · Cited by 42
Rodon, P., Hulin, C., Pegourie, B., Tiab, M., Anglaret, B., Benboubker, L., Jardel, H., Decaux, O., Kolb, B., Roussel, M., et al. (2015) · Haematologica · doi:10.3324/haematol.2014.110890 · Cited by 35
Self-citationWeisel, K. C., Doyen, C., Dimopoulos, M. A., Yee, A., Lahuerta, J. J., Martin, A. L., Travers, K. U., Druyts, E., Toor, K., Abildgaard, N., et al. (2016) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2016.1177772 · Cited by 35
“[16–18] Similar results were observed in the FIRST trial, where 44% of patients randomized to MPT reported grade 3/4 neutropenia compared with 28% in the Rd until progression group [5].”
BackgroundMethodResultInfluentialSelf-citationChanan-Khan, A. A., Zaritskey, A. Y., Egyed, M., Vokurka, S., Семочкин, С. В., Schuh, A., Kassis, J., Simpson, D., Zhang, J., Purse, B., et al. (2017) · The Lancet Haematology · doi:10.1016/s2352-3026(17)30168-0 · Cited by 39
Induction Therapy for Newly Diagnosed Multiple Myeloma
Paul, B. A., Lipe, B. C., Ocio, E. M., & Usmani, S. Z. (2019) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_238527 · Cited by 38
Advances in Management for Older Adults With Hematologic Malignancies
Rosko, A. E., Córdoba, R., Abel, G. A., Artz, A. S., Loh, K. P., & Klepin, H. D. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.00242 · Cited by 38
Менделеева, Л. П., Votyakova, O. M., Rekhtina, I. G., Osmanov, E. A., Poddubnaya, I. V., Гривцова, Л. Ю., Falaleeva, N. A., Байков, В. В., Kovrigina, A. M., Nevol’skikh, A. A., et al. (2021) · Journal of Modern Oncology · doi:10.26442/18151434.2020.4.200457 · Cited by 40
Treatment horizon in multiple myeloma
Soekojo, C. Y., & Chng, W. J. (2022) · European Journal Of Haematology · doi:10.1111/ejh.13840 · Cited by 40
“Significant improvements in PFS and OS were observed in the lenalidomide arm compared to the MPT arm.(62,63) Subsequently, the SWOG S0777 phase 3 study assessed the addition of bortezomib, randomizing patients to receive bortezomiblenalidomide-dexamethasone or lenalidomide-dexamethasone combinations.”
Optimizing current and emerging therapies in multiple myeloma: a guide for the hematologist
Raza, S., Safyan, R. A., E, E. R. P., Bowman, C. A., & Lentzsch, S. (2016) · Therapeutic Advances in Hematology · doi:10.1177/2040620716680548 · Cited by 40
“The most sensitive techniques, such as next generation flow cytometry and next generation sequencing, have the potential to achieve a detection sensitivity up to 1 in 106 cells with an improved quantifiable range [Biran et al. 2014].”
MethodTreating Multiple Myeloma Patients With Oral Therapies
Kumar, S. K., Vij, R., Noga, S. J., Berg, D. T., Brent, L. D., Dollar, L. E., & Chari, A. (2017) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2017.02.024 · Cited by 37
“or cyclophosphamide and dexamethasone).(4,15-19) Although the triplet regimens lenalidomide plus melphalan and prednisone and lenalidomide, cyclophosphamide, and prednisone have shown little benefit over the standard of care, lenalidomide and dexamethasone (Rd),(20) several studies have demonstrated that an immunomodu…”
BackgroundRichardson, P. G. G., Hofmeister, C. C., Rosenbaum, C. A., Htut, M., Vesole, D. H., Berdeja, J. G., Liedtke, M., Chari, A., Smith, S. D., Lebovic, D. J., et al. (2018) · British Journal of Haematology · doi:10.1111/bjh.15394 · Cited by 36
Baertsch, M., Mai, E. K., Hielscher, T., Bertsch, U., Salwender, H. J., Munder, M., Fuhrmann, S., Dührsen, U., Brossart, P., Neben, K., et al. (2021) · Blood Cancer Journal · doi:10.1038/s41408-020-00390-3 · Cited by 36
Self-citationStraka, C., Liebisch, P., Salwender, H. J., Hennemann, B., Metzner, B., Knop, S. T., Adler-Reichel, S., Gerecke, C., Wandt, H., Bentz, M., et al. (2016) · Haematologica · doi:10.3324/haematol.2016.151860 · Cited by 41
The role of maintenance therapy in multiple myeloma
Lipe, B. C., Vukas, R. R., & Mikhael, J. R. (2016) · Blood Cancer Journal · doi:10.1038/bcj.2016.89 · Cited by 36
Bringhen, S., D’Agostino, M., Paoli, L. D., Montefusco, V., Liberati, A. M., Galieni, P., Grammatico, S., Muccio, V. E., Esma, F., Angelis, C. D., et al. (2017) · Leukemia · doi:10.1038/leu.2017.327 · Cited by 33
Wang, Q., Lin, Z., Wang, Z., Ye, L., Xian, M., Xiao, L., Pan, S., Bi, E., Huang, Y.-H., Qian, J., et al. (2021) · Blood · doi:10.1182/blood.2020009856 · Cited by 33
Improved survival in multiple myeloma during the 2005–2009 and 2010–2014 periods
Corre, J., Perrot, A., Hulin, C., Caillot, D., Stoppa, A., Facon, T. T. F., Leleu, X. P., Dib, M., Karlin, L., Moreau, P., et al. (2021) · Leukemia · doi:10.1038/s41375-021-01250-0 · Cited by 32
Self-citationDimopoulos, M. A., Grosicki, S., Wiktor-Jędrzejczak, W., Nahi, H., Gruber, A., Hansson, M., Gupta, N., Byrne, C., Labotka, R., Teng, Z., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.09.011 · Cited by 34
Self-citationCosta, F., Vescovini, R., Bolzoni, M., Marchica, V., Storti, P., Toscani, D., Accardi, F., Notarfranchi, L., Palma, B. D., Manferdini, C., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.18085 · Cited by 36
Chakraborty, R., Muchtar, E., Kumar, S. K., Buadi, F. K., Dingli, D., Dispenzieri, A. A., Hayman, S. R., Hogan, W. J., Kapoor, P., Lacy, M. Q., et al. (2017) · Leukemia · doi:10.1038/leu.2017.256 · Cited by 36
Self-citationMignot, F., Schernberg, A., Arsene-Henry, A., Vignon, M., Bouscary, D., & Kirova, Y. M. (2019) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2019.10.043 · Cited by 35
Lenalidomide use in multiple myeloma (Review)
Zhang, C.-W., Wang, Y., & Ge, X. (2023) · Molecular and Clinical Oncology · doi:10.3892/mco.2023.2705 · Cited by 43
“For patients with NDMM, treatment with lenalidomide in combination with dexametha‑ sone was associated with a higher incidence of infection in the former compared with treatment with melphalan, pred‑ nisone, and thalidomide (MPT) (82,83).”
BackgroundResultAutologous haematopoietic cell transplantation in elderly patients with multiple myeloma
Auner, H. W., Garderet, L., & Kröger, N. M. (2015) · British Journal of Haematology · doi:10.1111/bjh.13608 · Cited by 32
Dimopoulos, M. A., Petrucci, M. T., Foà, R., Catalano, J., Kropff, M. H., Terpos, E., Zhang, J., Grote, L., Jacques, C. J., & Palumbo, A. (2015) · Haematologica · doi:10.3324/haematol.2014.120790 · Cited by 32
“analysis of the largest prospective randomized trial conducted in NDMM patients (FIRST trial), Benboubker et al.(12) similarly reported a significant improvement in median PFS2 with continuous lenalidomide and dexamethasone therapy compared with a fixed-duration regimen of MPT (42.”
MethodInfluentialSelf-citationCavo, M., Terpos, E., Bargay, J., Einsele, H., Cavet, J., Greil, R., & de Wit, E. (2018) · Expert Review of Hematology · doi:10.1080/17474086.2018.1437345 · Cited by 33
Self-citation
Metadata
- Authors
- Benboubker, L., Dimopoulos, M. A., Dispenzieri, A., Catalano, J., Belch, A. R., Cavo, M., Pinto, A., Weisel, K., Ludwig, H., Bahlis, N., Banos, A., Tiab, M., Delforge, M., Cavenagh, J., Geraldes, C., Lee, J.-J., Chen, C., Oriol, A., de la Rubia, J., Qiu, L., White, D. J., Binder, D., Anderson, K., Fermand, J.-P., Moreau, P., Attal, M., Knight, R., Chen, G., Van Oostendorp, J., Jacques, C., Ervin-Haynes, A., Avet-Loiseau, H., Hulin, C., & Facon, T.
- Affiliations
- National and Kapodistrian University of Athens (GR)
- Mayo Clinic (US)
- Frankston Hospital (AU)
- University of Alberta (CA)
- Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" (IT)
- University of Tübingen (DE)
- Wilhelminen Hospital (AT)
- University of Calgary (CA)
- Centre Hospitalier de la Côte Basque (FR)
- Universitair Ziekenhuis Leuven (BE)
- St Bartholomew's Hospital (GB)
- Unidade Local de Saúde de Coimbra (PT)
- Chonnam National University Hwasun Hospital (KR)
- Princess Margaret Cancer Centre (CA)
- Josep Carreras Leukaemia Research Institute (ES)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Dalhousie University (CA)
- Kantonsspital Winterthur (CH)
- Dana-Farber Cancer Institute (US)
- Hôpital Saint-Louis (FR)
- Hôpital Purpan (FR)
- Celgene (United States) (US)
- Centre Hospitalier Régional et Universitaire de Nancy (FR)
- Centre Hospitalier Universitaire de Lille (FR)
- ORCID
- Benboubker, Lotfi
- Dimopoulos, Meletios A.
- Dispenzieri, Angela
- Belch, Andrew R.
- Weisel, Katja
- Ludwig, Heinz
- Bahlis, Nizar
- Banos, Anne
- Geraldes, Catarina
- Lee, Je-Jung
- Chen, Christine
- Oriol, Albert
- Qiu, Lugui
- White, Darrell J.
- Anderson, Kenneth
- Fermand, Jean-Paul
- Moreau, Philippe
- Attal, Michel
- Knight, Robert
- Chen, Guang
- Jacques, Christian
- Hulin, Cyrille
- Facon, Thierry
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-09-04
- Volume
- 371
- Issue
- 10
- Pages
- 906-917
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2141105112
- Cited by
- 793
- References
- 38
- Citations by year
- 2026: 18 · 2025: 41 · 2024: 39 · 2023: 37 · 2022: 54 · 2021: 74 · 2020: 89 · 2019: 75 · 2018: 80 · 2017: 92 · 2016: 102 · 2015: 76 · 2014: 15
- FWCI
- 67.35
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Keywords
- lenalidomide, dexamethasone, multiple myeloma, transplant-ineligible patients, progression-free survival, overall survival, treatment duration, adverse events, second primary malignancy, infection, neurotoxicity, hematologic toxicity, newly diagnosed multiple myeloma
- MeSH terms
- Lenalidomide, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Dexamethasone, Female, Humans, Male, Melphalan, Middle Aged, Multiple Myeloma, Prednisone, Thalidomide, Disease-Free Survival, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.